# US 2021/0330737 A1 · Treatment of Rhinosinusitis with P-glycoprotein Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330737 A1
- Document ID: US20210330737A1
- Status: Published application
- Kind: A1
- Application number: 17/231,843
- Filed: 2021-04-15
- Published: 2021-10-28
- Earliest claimed: 2012-12-27
- Assignees: Massachusetts Eye and Ear Infirmary
- Applicants: Massachusetts Eye and Ear Infirmary
- Inventors: Benjamin S. Bleier
- Web page: https://patentgrep.com/patent/US20210330737A1

## CPC

- A61K 38/13: Cyclosporins
- A61K 9/0043: {Nose}
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4164: 1,3-Diazoles
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/65: Tetracyclines
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/20: Polysaccharides
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 11/02: Nasal agents, e.g. decongestants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.

## Claims

### Claim 1

A method of treating rhinosinusitis in a subject, the method comprising
identifying a subject having rhinosinusitis;
administering to the subject an effective amount of a P-glycoprotein inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has chronic rhinosinusitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the P-glycoprotein inhibitor inhibits the function of P-glycoprotein.

### Claim 4 (depends on 3)

The method of claim 3, wherein the P-glycoprotein inhibitor is PSC 833, R-verapamil, GF120918, VX-710, or MS-209.

### Claim 5 (depends on 3)

The method of claim 3, wherein the P-glycoprotein inhibitor is LY335979, OC144093, R101933, XR9051, or XR9576.

### Claim at position 6

-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the P-glycoprotein inhibitor is administered locally to the subject's nasal passage and sinuses.

### Claim 9 (depends on 8)

The method of claim 8, wherein the P-glycoprotein inhibitor is delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, or by spraying.

### Claim 10 (depends on 8)

The method of claim 8, wherein the P-glycoprotein inhibitor is administered to the subject as a P-glycoprotein inhibitor eluting implant surgically placed in the subject's nasal passage or sinuses.

### Claim 11 (depends on 10)

The method of claim 10, wherein the P-glycoprotein inhibitor eluting implant is bioabsorbable.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject having rhinosinusitis was identified by endoscopy.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject having rhinosinusitis was identified by computed tomography.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject having rhinosinusitis was identified by observing the subject's symptoms and duration of symptoms.

### Claim at position 14

-18. (canceled)

### Claim 19

A kit for treating rhinosinusitis in a subject, said kit comprising
a pharmaceutical composition comprising an effective amount of a P-glycoprotein inhibitor; and
a device for delivering the pharmaceutical composition to the subject's nasal passage and sinuses.

### Claim 20 (depends on 19)

The kit of claim 19, wherein said device delivers the pharmaceutical composition to the subject's nasal passage and sinuses in a liquid, nebulized, or aerosolized form.

### Claim 21 (depends on 1)

The method of claim 1, wherein the P-glycoprotein inhibitor is administered in combination with one or both of a corticosteroid and an antibiotic.

### Claim 22 (depends on 21)

The method of claim 21, wherein the corticosteroid is selected from dexamethasone, prednisone, prednisolone, triamcinolone, cortisol, budesonide, mometasone, fluticasone, flunisolide, and betamethasone.

### Claim 23 (depends on 21)

The method of claim 21, wherein the antibiotic is selected from erythromycin, doxycycline, tetracycline, penicillin, beta-lactam, macrolide, fluoroquinolone, cephalosporin, and sulfonamide.

### Claim 24 (depends on 1)

The method of claim 1, wherein the P-glycoprotein inhibitor is administered in combination with a corticosteroid and an antibiotic.

### Claim 25 (depends on 19)

The kit of claim 19, further comprising a corticosteroid.

### Claim 26 (depends on 19)

The kit of claim 19, further comprising an antibiotic.
